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Abstract 
Objectives 
We sought to investigate non-coronary vascular calcification and its influence on 
changes in vascular inflammation. 
Background 
Atherosclerosis is an inflammatory condition with calcification apparent late in the 
disease process. The extent and progression of coronary calcification predict 
cardiovascular events. Relatively little is known about non-coronary vascular 
calcification.  
Methods 
One hundred and thirty participants in the dal-PLAQUE study underwent 
fluorodeoxyglucose positron emission tomography/computed tomography at entry 
and at 6 months. Calcification of the ascending aorta, arch, carotid, and coronary 
arteries was quantified. Cardiovascular risk factors were related to arterial 
calcification. The influence of baseline calcification and drug therapy (dalcetrapib vs. 
placebo) on progression of calcification was determined. Finally, baseline 
calcification was related to changes in vascular inflammation.  
Results 
Age >65 years was consistently associated with higher baseline calcium scores. 
Arch calcification trended to progress more in those with calcification at baseline (p = 
0.055). There was no significant difference in progression of vascular calcification 
with dalcetrapib as compared to placebo. Average carotid target-to-background ratio 
indices declined over 6 months if carotid calcium was absent (single hottest slice [p = 
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0.037], mean of maximum target-to-background ratio [p = 0.010], and mean most 
diseased segment [p = <0.001]), but did not significantly change if calcification was 
present at baseline.  
Conclusions 
Across multiple arterial regions, higher age is consistently associated with higher 
calcium scores. The presence of vascular calcification at baseline is associated with 
progressive calcification; in the carotid arteries, calcification appears to influence 
vascular inflammation. Dalcetrapib therapy did not affect vascular calcification. 
 
Key words (3-5): Atherosclerosis; calcium; inflammation; dalcetrapib 
Categories (1-3): 1. Vascular Disease, Hypertension and 
Prevention/Pharmacology/Hormones/Lipids – Clinical; 2. Vascular Disease, 
Hypertension and Prevention/Vascular/Pathology - Clinical 
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Abbreviations and Acronyms 
BMI = body mass index 
CHD = coronary heart disease 
HDL = high-density lipoprotein 
FDG = 18F-fluorodeoxyglucose 
LDL = low-density lipoprotein 
MDS = most diseased segment 
PET/CT = positron emission tomography/computed tomography 
SHS = single hottest slice 
SUV = standardized uptake value 
TBR = target-to-background ratio 
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Introduction 
Atherosclerosis is a chronic, systemic, multifocal inflammatory disorder, a response 
to the deposition of low-density lipoprotein (LDL) in the vascular wall. Thought to be 
an actively-inhibited but passive process of mineralization (1), there is increasing 
evidence that arterial calcification is an active and regulated process analogous to 
bone formation. That supposition is supported by histologic findings of ectopically-
formed bone, the presence of osteoblast and osteoclast-like cells, and the secretion 
of several bone-related peptides within calcified atherosclerotic lesions. In pre-
clinical models, inflammatory macrophage activity is seen to precede early 
osteogenesis (2). 
Vascular calcification serves as a marker for the extent of atherosclerosis, and is 
predictive of cardiovascular events and mortality (3,4). Calcification of the coronary 
arteries has been extensively investigated. In clinical practice, coronary calcium 
scoring is used to risk-stratify patients for coronary heart disease (CHD), providing 
better discrimination than classical risk factors alone (4). 
By comparison, relatively little is known about vascular calcification and its 
progression in other arterial regions. Contrary to notion that calcification represents a 
stable, end-stage of the disease, dynamic micro-calcification may increase the risk of 
plaque rupture and clinical events (5). Understanding this process is important 
because rapid progression of calcification, at least in the coronary arteries, is 
associated with an increased risk of cardiovascular events. Current medical 
therapies, including statins, do not alter this progression (6,7). 
In this study we investigated vascular calcification detected on serial positron 
emission tomography/computed tomography (PET/CT) imaging in the dal-PLAQUE 
 7 
study, a phase 2 randomized clinical trial that investigated the effects of the 
cholesteryl ester transfer protein inhibitor, dalcetrapib, on the vasculature.  
Specifically, we hypothesised (1) that the presence of classical cardiovascular risk 
factors would increase both baseline calcification and its progression in the 
ascending aorta, aortic arch, and carotid and coronary arteries over 6 months. We 
also hypothesized (2) that arteries with the highest baseline calcium levels would 
undergo the greatest additional calcification over the next 6 months.  
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Methods 
The current study is a post hoc analysis of the dal-PLAQUE study. The study design, 
methods and primary results have already been published (8,9). dal-PLAQUE was a 
phase 2b, double-blind, randomized, placebo-controlled study that investigated the 
effect of dalcetrapib on vessel wall inflammation assessed by 18F-fluorodeoxyglucose 
(FDG) PET/CT. Inclusion criteria were males and females aged 18 to 75 years, with 
previous known CHD or at high risk thereof (diabetes or a 10-year risk of CHD 
events >20% by Framingham Risk scoring), triglyceride concentrations ≤400 mg/dl, 
LDL cholesterol (LDL-C) concentrations <100 mg/dl or on maximum tolerated doses 
of statins, and a target to background ratio (TBR) of 1.6 or higher in an index vessel 
(either right carotid, left carotid, or ascending aorta), as identified by 18F-FDG uptake 
measured by PET/CT during the screening period.  
PET/CT imaging 
Details of FDG PET/CT imaging procedures, quantification of tracer uptake, and 
analyses have been published previously (8). FDG-PET/CT imaging of the carotid 
arteries and ascending aorta was performed at baseline as well as after 3 and 6 
months of follow-up.  
Arterial FDG uptake was quantified by manually delineating a region of interest (ROI) 
on co-registered transaxial PET/CT images. A circular ROI was drawn to encompass 
the vessel wall on each contiguous axial segment. Next, the maximum arterial 
standardized uptake value (SUV) was determined, being defined as the decay-
corrected tissue concentration of FDG in kBq/ml, adjusted for the injected FDG dose 
and the body weight of the patient. We calculated TBR from the ratio of SUV of the 
artery compared with background venous activity and recorded values for the 
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individual vessels (aorta and mean right and left carotid artery) using previously 
reported methods (8). The vessel with the highest maximum TBR at baseline was 
considered the index vessel. Mean of maximum (MeanMax) TBR was the average of 
the maximal TBR values from each artery. The most diseased segment (MDS) was 
defined as the average maximum TBR of a group of 3 contiguous slices, centered on 
the slice with the highest maximum TBR, the single hottest slice (SHS). Active slices 
were defined as those with TBR >1.6. For the current analyses, we used baseline 
values and change in the above indices at 6 months for both the index vessel and an 
average of both carotid arteries.  
Assessment of vascular calcification 
Analysis was performed on baseline and 6-month CT scans by an experienced 
observer (Francis R Joshi) blinded to both clinical details and scan order. 
Unenhanced CT imaging acquired for localization of FDG PET uptake was loaded 
into the open-source DICOM viewer OsiriX (version 4.0, 64-bit, OsiriX Imaging 
Software, Geneva, Switzerland) and re-sampled to a 3 mm transaxial thickness.  
Using the freely available ‘Calcium Scoring’ plug-in, vascular calcification (based on 
an attenuation threshold of 130 Hounsfield Units in 3 contiguous voxels, after the 
method of Agatston (10)) was analyzed on consecutive transaxial slices along the 
length of the arterial segment. The extent of calcification was expressed both as a 
score in Agatston units and as a volume in cubic millimeters. The measurement of 
thoracic aortic and coronary artery calcification from ungated CT studies is accurate 
and highly concordant with values derived from gated studies (11). Paired (baseline 
and follow-up) studies were visually compared to ensure that the same length of 
artery was analyzed on both scans. 
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Coronary artery calcification was scored as the sum of all 3 epicardial vessels. 
Ascending aortic calcification was scored on transaxial slices from the main 
pulmonary artery inferiorly to 1 slice below the aortic arch. Aortic arch calcification 
was scored on transaxial slices from the most inferior slice at which the ascending 
and descending aorta were contiguous to the origin of the great vessels. Calcification 
was scored if it appeared to be in the vascular wall. When isolated calcification of the 
ligamentum arteriosum was obvious it was not scored. Carotid arterial calcification 
was assessed bilaterally from the most inferior slice visible on the CT scan to the 
base of the skull, and then summed. 
Coronary calcium was not recorded in those who had undergone prior percutaneous 
coronary intervention or coronary artery bypass surgery. If the participant had 
evidence of prior coronary bypass surgery, the ascending aorta was not analysed, 
due to artefacts from the surgical clips used in fashioning the grafts. If possible, 
calcification in the aortic arch was still scored in such cases, provided there were no 
significant artefacts from sternal wires or surgical clips. Noisy CT images of the neck, 
with artefacts from dental prostheses, were excluded from analyses of the carotid 
arteries. 
Statistical analysis 
Descriptive data are presented as median (Q1, Q3) as well as frequencies with 
proportions for nominal variables as appropriate. 
The following measures of progression of vascular calcification were used: 
1. The absolute difference between baseline and follow-up 
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2. The difference between the square root of baseline and square root of follow-
up score (the ‘SQRT method’ of Budoff et al (12)). A cut-off of 2.5 was used to 
identify a change in calcification from baseline beyond the known interscan variability 
of coronary calcium scores, as per Hokanson et al. (13). 
Baseline calcium scores in the presence or absence of risk factors were compared 
after square root transformation using analysis of variance (ANOVA). Baseline 
calcium scores were dichotomized into ‘zero’ and ‘non-zero’, and the effect of a non-
zero score on progression of calcification (absolute change after square root 
transformation) was analyzed using ANOVA. The effect of a  ‘non-zero’ score on 
absolute changes in PET indices at 3 and 6 months were assessed through linear 
mixed models with a visit by score interaction. The effect of dalcetrapib treatment on 
calcium progression (absolute change on original scale and also after square root 
transformation) was analyzed using ANOVA with baseline and treatment in the 
model. Two-sided p-values are reported throughout, with no adjustment for multiple 
testing. The lack of adjustment for multiple testing was pre-planned and stated in our 
statistical analysis plan for all Dalplaque manuscripts (8), (9). Here, we provide raw p 
values that should be interpreted in the light of multiple testing. 
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Results 
dal-PLAQUE recruited 130 patients with a median age of 65 years, most (82%) of 
whom were male. Baseline demographics are reported in Table 1. After exclusions, 
both baseline and 6-month CT images yielded data for the aortic arch in 98 patients 
(75%), the ascending aorta in 80 patients (62%), the carotid arteries in 102 patients 
(78%), and the coronary arteries in 32 patients (25%). Data were only included when 
the whole arterial territory was visualized on both PET/CT scans. 
At baseline, the median (Q1, Q3) calcium score in the aortic arch was 161 (0, 852), 
in the combined carotid arteries 52 (0, 267) and 13 (0, 83) in the coronary arteries. 
The median (Q1, Q3) calcium score in the ascending aorta was 0 (0, 0). Given the 
large number of zero scores (71 of 80 participants), it was not possible to analyze 
associations between cardiovascular risk factors and the baseline scores in the 
ascending aorta. Across all other arterial territories, baseline calcium scores were 
higher in those over the age of 65 as compared to younger participants (Table 2). 
Scores in the aortic arch were significantly higher in those having ever smoked (329 
[43, 1073] vs. 0 [0, 551]; p = 0.003 after SQRT transformation). Calcium scores were 
higher in those with body mass index (BMI) ≤29 kg/m2 than in those with BMI >29 
kg/m2 in the carotid arteries (132 (3, 411) vs. 7 [0, 158]; p = 0.007 after SQRT 
transformation) but not elsewhere. An LDL-C >80 mg/dl was not associated with 
significantly higher baseline calcium scores than those with LDL-C ≤80 mg/dl; 
additionally, high-density lipoprotein cholesterol (HDL-C) levels ≤40 mg/dl were not 
significantly associated with higher calcium scores than levels >40 mg/dl. A history of 
CHD, hypertension, type 2 diabetes, peripheral arterial disease, or metabolic 
syndrome was not associated with higher baseline calcium scores in any territory. 
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‘New’ calcification was seldom seen at 6 months in those with no calcium at 
baseline. This only occurred in 3 of 32 patients (9%) in the coronary circulation and 
in the carotids in 5 of 102 patients (5%). There was no incident calcification in those 
with zero baseline scores in either the ascending aorta or aortic arch. 
Across both treatment groups, progression of SQRT volumes >2.5 was noted in 12 
of 32 patients (38%) in the coronary arteries, 18 of 98 patients (18%) for the aortic 
arch, and 3 of 104 patients (3%) the carotid arteries. 
There was a trend towards greater progression of calcium scores after SQRT 
transformation in the aortic arch in those with non-zero scores at baseline compared 
to zero at baseline (p = 0.055, Table 3).  
Treatment assignment was not associated with a significant difference in progression 
of calcium scores in any arterial territory (Table 4; similar data for calcium volumes 
not shown).  
Comparing difference in absolute change in average carotid PET indices from 
baseline to 6 months, TBR in active slices (p < 0.001), SHS (p = 0.006), 
MeanMaxTBR (p = 0.003) and mean MDS (p = 0.008) declined if baseline total 
carotid calcium was zero, relative to those with non-zero scores (Table 5). At 6 
months, average carotid PET indices consistently declined in those with zero total 
carotid calcium scores (mean active segment TBR [p < 0.001], SHS TBR [p = 0.037], 
mean MDS TBR [p < 0.001], and MeanMax TBR [p = 0.010]; Figure 1). There was 
no statistically significant change (p > 0.05) in these indices for those with non-zero 
scores. The presence or absence of calcification elsewhere did not influence 
changes in measures of carotid PET uptake. Additionally, there was no significant 
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relationship between baseline calcification and change in measures of inflammation 
for the index vessel (ascending aorta in 75% of cases; data not shown). 
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Discussion 
The study investigated the relationship between risk factors and vascular 
calcification in several arterial territories, and explored the relationship between 
baseline calcification and changes in inflammation on serial FDG-PET/CT imaging. 
Whilst prior studies have reported the relationship between arterial calcification and 
cardiovascular risk factors, and progression of calcification in a single arterial 
territory (usually coronary), the imaging undertaken in the dal-PLAQUE study 
afforded an opportunity to examine both these questions. In addition, the first data on 
progression of aortic calcification outside of renal disease are reported. 
Consistently, age >65 years was significantly associated with higher baseline arterial 
calcification. Generally, the same cardiovascular risk factors influenced 
atherosclerosis in the coronary, aortic arch and carotid circulation, as also noted by 
others (3,14,15). Data from the Rotterdam Study found that age and current smoking 
were the strongest risk factors for calcification in all vessel beds, except the 
coronaries. Additionally, hypertension, hypercholesterolemia, and diabetes are 
independently related to arterial calcification, although associations are not 
consistent across all vessel beds and for men and women (14). Increasing thoracic 
aortic scores were observed with increasing age in a study by Rivera et al. (15). 
Most traditional cardiovascular risk factors, including age, diabetes, hypertension, 
smoking, and family history, were significantly associated with the presence of aortic 
calcification, though not LDL-C or HDL-C. Aortic calcification was also associated 
with incident (new) coronary calcification predicting all-cause mortality (16) and 
cardiovascular events, though not as strongly as coronary artery calcium (17).  
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An inverse association with a high BMI and carotid arterial calcification was noted in 
our study. Associations of BMI and vascular calcification have generally been 
inconsistent (18–21), describing positive, inverse, or no association. The ‘obesity 
paradox’ for cardiovascular risk is well-described (22). Though mechanistic insight is 
lacking, it has been proposed that, in females, estrogen production in adipose tissue 
is relatively protective for the vasculature (23). 
Progression of vascular calcification has the potential to better capture the temporal 
exposure to risk factors as compared with a single baseline score. It has been 
suggested that a baseline calcium score can be thought of as a single point on an 
atherosclerosis-versus-time curve, whereas progression correlates with the slope of 
that curve (24). Similarly, although baseline scores might reflect the atherosclerotic 
plaque burden, progression might provide insight into ongoing current disease 
activity. Rapid progression of coronary calcium scores is independently predictive of 
mortality (12). Our study demonstrated very little newly detectable calcification at 6 
months in those without it at baseline, presumably due to the relatively short interval 
between scans. Nevertheless, our data are consistent with those of Min et al., who 
demonstrated that, in subjects over 45 years of age, approximately 5% of those 
without detectable coronary calcium on CT would develop it over 12 months, largely 
dependent on the number of cardiovascular risk factors present (25). 
In those with some degree of calcium at baseline, there were larger increases in 
calcium scores within the aortic arch and right carotid arteries compared to those 
with non-zero scores in the same arteries at the start of the study. To the best of our 
knowledge, these are the first published data on the progression of aortic 
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calcification outside of the context of end-stage kidney disease or renal 
transplantation (26).  
Van Gils et al. published work describing the progression of carotid calcification in 
patients after transient ischemic attack or stroke, with 4.7 years between scans (27). 
Calcification was measured on contrast-enhanced CT scans, using a threshold of 
600 Hounsfield units to define calcium. Incident calcification was seen in around 40% 
of those with zero calcium at baseline over the follow-up period, and was associated 
with advanced age and hypertension at baseline. Similarly, the most important 
determinant of progression of existing calcification was the baseline calcium score, 
although age, diabetes, hypertension, and smoking were also significantly 
associated. There are no published data on the prognostic implications of carotid 
artery calcification. Data regarding its relationship to luminal stenosis are conflicting 
(28,29). 
There was no significant difference in progression of vascular calcification in any 
arterial territory with dalcetrapib as compared to placebo. In vitro, HDL-C inhibits 
osteogenic differentiation and calcification of vascular smooth muscle cells (30). 
Kuller et al. found an independent association of HDL-C with coronary calcification in 
postmenopausal females (31), though there is no evidence for an association with 
calcification elsewhere (14). 18F-sodium fluoride has been advocated as a means of 
non-invasively detecting active calcification in vivo (32). 18F-sodium fluoride uptake in 
the coronary arteries in that study was associated with a low HDL-C, suggesting that 
this might be permissive for progressive calcification. Further research is required to 
investigate this; to date, however, pharmacological treatment of low HDL-C has not 
influenced clinical outcomes (33,34).  
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Over the 6 month interval from first to last PET scan in the dal-PLAQUE study, 
carotid artery TBR indices consistently declined in patients without carotid 
calcification at baseline, but remained statistically unchanged when calcification was 
already present. Calcification in other arterial territories did not appear to influence 
changes in carotid inflammation, suggesting a local interaction. Inflammation and 
calcification are thought to be active at different phases of the disease process in 
atherosclerosis. Inflammation appears to be dominant early, leading to development 
and maturation of plaques, with calcification predominant later. Pre-clinical models 
have demonstrated this spatial and temporal relationship (2). Initial deposition of 
calcium hydroxyapatite, so-called microcalcification, may induce further inflammatory 
responses (35). Whilst linked, inflammation and calcification are distinct processes 
within atherosclerosis, and medium-term changes in the relative importance of each 
in vivo are not well understood. Recent work by Abdelbaky et al. suggests that local 
vascular inflammation as assessed by FDG PET is independently associated with 
progression of thoracic aortic calcification (36). In this study, arterial segments with 
subsequent incident calcification had the highest baseline FDG uptake, suggesting 
that inflammation precedes calcification. Furthermore, within individuals, arterial 
segments with progressive calcification from a non-zero baseline had the highest 
FDG uptake. This suggests that inflammation continues to be important after the 
development of macroscopic calcification. Segments with calcification that did not 
progress had the lowest FDG uptake. This is consistent with previous work showing 
that the final stages of calcification are associated with a reduction in inflammatory 
activity (37). The point at which inflammation becomes less prominent is, however, 
still to be defined. 18F-sodium fluoride holds promise as a means of imaging active 
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calcification in vivo (38) and further longitudinal study of changes in the activity of 
both inflammation and calcification is needed to better understand these processes. 
Limitations 
This was a post-hoc analysis of data from the dal-PLAQUE study, with only 6 months 
between PET/CT imaging sessions. Consequently, despite the inclusion of a high-
risk population, there was relatively little progression of vascular calcification during 
this short wondow. A significant number of scans were excluded from analysis of the 
coronary arteries because of prior coronary bypass surgery or coronary intervention. 
Whilst coronary calcium scores on electrocardiogram-gated and ungated CT scans 
are highly correlated, the interscan variability on ungated scans is not known. 
Comparison of ungated scans may therefore miss small increments in coronary 
calcium scores, but is likely to be less of a problem in the other vascular beds 
studied. Finally, as in any post-hoc data analysis, false positive findings are possible. 
We advise caution in interpretation of our results, which need to be replicated in 
longer, larger, prospective studies. 
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Conclusions 
Inflammation and calcification are important in both the progression of 
atherosclerosis and its clinical complications. 
In this study, we have described the relationship between cardiovascular risk factors 
and both baseline and interval calcification in several arterial beds, as well as the 
interactions with inflammation in those territories. We have also provided data 
concerning the drivers of calcification progression and the lack of a significant effect 
of an HDL-raising therapy on calcification. Finally, we have provided the first report 
of aortic calcification progression outside of the context of subjects with renal failure. 
These findings are important for providing a better understanding of the links 
between these pathological processes, and could help to improve both patient risk-
stratification and provide a platform for developing and testing new atherosclerosis 
treatments. 
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Table 1. Baseline Demographics 
 Placebo 
(n = 66) 
Dalcetrapib 
(n = 64) 
Overall 
(n = 130) 
Demographics    
Age, years 64.6 (61, 71) 62.6 (60, 68) 63.6 (60, 70) 
Male sex 55 (83) 51 (80) 106 (82) 
Body mass index, kg/m
2
 29.8 (25.5, 32.3) 29.6 (25.9, 32.1) 29.7 (25.7, 32.2) 
White race 62 (94) 58 (91) 120 (92) 
History of 
Coronary heart disease 54 (82) 57 (89) 111 (87) 
Symptomatic coronary artery 
disease 
5 (8) 5 (8) 10 (8) 
Hypertension 48 (73) 47 (73) 95 (74) 
Type 2 diabetes 20 (30) 19 (30) 39 (30) 
Abdominal aortic aneurysm 2 (3) 3 (5) 5 (4) 
Peripheral artery disease 10 (15) 6 (9) 16 (12) 
Current smoker 8 (12) 9 (14) 17 (13) 
Statin use 61 (92) 52 (81) 113 (87) 
Imaging parameters at baseline 
Average carotid FDG-PET/CT 
MeanMax TBR 1.76 (1.47, 2.10) 1.79 (1.58, 2.21) 1.78 (1.50, 2.19) 
Single hottest slice 1.96 (1.70, 2.40) 2.01 (1.83, 2.45) 2.00 (1.73, 2.44) 
Calcium scores, AU 
Ascending aorta 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Aortic arch 157 (0, 797) 166 (0, 865) 161 (0, 852) 
Coronary arteries 16 (0, 89) 10 (0, 58) 13 (0, 83) 
Total carotid arteries 100 (0, 315) 27 (1, 234) 52 (0, 267) 
Data are presented as median (Q1, Q3) for continuous variables and as n (%) otherwise. 
AU = Agatston units; FDG-PET/CT = fluorodeoxyglucose positron emission tomography/computed tomography; 
MeanMax, mean of maximum; TBR = target-to-background ratio.
Table 2. Summary of Baseline Calcium Scores by Cardiovascular Risk Factors 
  Aortic Arch Coronary Arteries Total Carotid Arteries 
  n Score (AU) p Value* n Score (AU) p Value* n Score (AU) p Value* 
Age (years) ≤65 53 15 (0, 280) <0.001 17 8 (0, 21) 0.038 55 7 (0, 100) <0.001 
 >65 45 651 (165, 1181)  15 58 (0, 204)  48 175 (18, 427)  
Body mass 
index (kg/m
2
) 
≤29 48 261 (2, 941) 0.107 14 10 (0, 89) 0.750 50 132 (3, 411) 0.007 
>29 50 83 (0, 775)  18 19 (0, 76)  53 7 (0, 158)  
Coronary 
heart disease 
Yes 86 161 (0, 797) 0.733 20 13 (0, 111) 0.617 90 45 (0, 267) 0.611 
No 12 148 (2, 860)  12 15 (0, 67)  13 68 (0, 249)  
Hypertension Yes 74 165 (0, 852) 0.705 24 10 (0, 62) 0.078 79 54 (2, 276) 0.750 
No 24 57 (2, 930)  8 53 (2, 301)  24 13 (0, 216)  
Type 2 
diabetes 
Yes 31 200 (0, 1022) 0.457 15 4 (0, 76) 0.488 32 41 (4, 210) 0.565 
No 67 135 (0, 775)  17 21 (1, 93)  71 54 (0, 315)  
Peripheral 
arterial 
disease 
Yes 13 280 (0, 865) 0.249 5 10 (1, 204) 0.562 13 100 (29, 423) 0.128 
No 85 135 (0, 781)  27 16 (0, 76)  90 49 (0, 249)  
Current 
smoker 
Yes 10        510 (43, 1079) 0.127 3 4 (0, 10) 0.262 11 34 (4, 173) 0.605 
No 88 118 (0, 789)  29 21 (0, 89)  92 54 (0, 272)  
Ever smoked Yes 57   329 (43, 1073) 0.003 20 19 (1, 109) 0.349 58 69 (4, 276) 0.334 
 No 41 0 (0, 551)  12 5 (0, 67)  45 29 (0, 224)  
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Metabolic 
syndrome 
Yes 53 157 (3, 871) 0.650 20 13 (0, 62) 0.495 57 25 (0, 254) 0.185 
No 45 166 (0-651)  12 29 (1, 109)  46 106 (0, 267)  
HDL-C   
(mg/dl) 
<=40 38 214 (3, 1011) 0.549 11 47 (0, 265) 0.279 42 27 (3, 315) 0.683 
>40 60 150 (0, 753)  21 9 (0, 48)  61 66 (0, 254)  
LDL-C (mg/dl) <=80 65 100 (0, 775) 0.295 19 9 (0, 204) 0.391 69 54 (0, 276) 0.460 
>80 33 200 (0, 1002)  13 23 (0, 48)  34 33 (0, 249)  
Data are presented as median (Q1, Q3). No data are presented for the ascending aorta because calcium scores at baseline were zero in 71 of 80 participants. *p-values are 
two-sided after square root transformation. 
AU = Agatston units; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol.
Table 3. Progression in Vascular Calcification over 6 Months by Baseline (Zero 
vs. Non-Zero) Calcium Score and Volume 
 Zero at Baseline Non-Zero at Baseline  
 n (%) Median 
Absolute 
Change 
n (%) Median 
Absolute 
Change 
p Value* 
Calcium scores (AU)     
Ascending 
aorta 
71 (89) 0 (0, 0) 9 (11) 0 (-10, 29) 0.900 
Aortic 
arch 
29 (30) 0 (0, 0) 69 (70) 13 (-15, 138) 0.055 
Coronary 
arteries 
11 (34) 0 (0, 0) 21 (66) 10 (-5, 68) 0.414 
Left 
carotid 
39 (38) 0 (0, 0) 64 (62) 0 (-11, 21) 0.774 
Right 
Carotid 
43 (42) 0 (0, 0) 59 (58) 5 (-2, 23) 0.029 
Total 
carotid 
arteries 
28 (27) 0 (0, 0) 74 (73) 3 (-5, 33) 0.249 
Calcium volumes (mm
3
)     
Ascending 
aorta 
71 (89) 0 (0, 0) 9 (11) 3 (-11, 9) 0.536 
Aortic 
arch 
29 (30) 0 (0, 0) 69 (70) 14 (-35, 121) 0.356 
Coronary 
arteries 
11 (34) 0 (0, 0) 21 (66) 6 (-17, 187) 0.648 
Left 
carotid 
39 (38) 0 (0, 0) 64 (62) 4 (-8, 23) 0.995 
Right 
carotid 
43 (42) 0 (0, 0) 59 (58) 8 (-3, 34) 0.006 
Total 
carotid 
arteries 
28 0 (0, 0) 74 10 (-8, 31) 0.225 
Data are presented as n (%) and median (Q1, Q3). *p-values are two-sided after square root transformation. 
AU = Agatston units. 
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Table 4. Effect of Treatment with Dalcetrapib on Progression of Calcium 
Scores over 6 Months 
 Absolute 
Change from 
Baseline* 
p Value Change from 
Baseline after 
SQRT 
p Value 
Ascending 
aorta 
-6 (-19 to 7) 0.355 0.17 (-0.73 to 0.38) 0.538 
Aortic arch 83 (-4 to 171) 0.061 0.74 (-0.54 to 2.02) 0.254 
Coronary 
arteries 
-61 (-171 to 48) 0.263 -1.51 (-4.64 to 1.61) 0.330 
Total carotid 
arteries 
6 (-10 to 21) 0.459 0.28 (-0.18 to 0.74) 0.231 
Data are presented as difference from placebo with (95% CI). Two-sided p values.  
*Absolute change in Agatston
 
units.  
CI = confidence interval; SQRT = square root transformed values.  
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Table 5. Comparison of Change in Average Carotid 18F-FDG PET Indices from 
Baseline to 6 Months for Patients with Zero and Non-Zero Baseline Total 
Carotid Calcium Scores 
 Mean Difference 
(95% CI) 
p-value 
Mean active segment TBR -0.23 (-0.35 to -0.11) <0.001 
Single hottest slice TBR -0.24 (-0.41 to -0.07) 0.006 
Mean MDS TBR -0.18 (-0.31 to -0.05) 0.008 
MeanMax TBR -0.18 (-0.30 to -0.06) 0.003 
Data are presented as mean difference (zero baseline scores minus non-zero) with (95% CI). Two-sided p-
values.  
FDG = fluorodeoxyglucose; TBR = target-to-background ratio; CI = confidence interval; MDS = most diseased 
segment; MeanMax, mean of maximum.  
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Figure 1. Change in Average Carotid 18F-FDG PET Indices from Baseline at 3 
and 6 Months by Baseline Total Carotid Calcium Score (Zero or Non-Zero).  
 
A: Change in mean active segment (TBR >1.6) TBR. Zero calcium scores, p = <0.001; non-zero scores p = 
0.399. 
B: Change in single hottest slice TBR. Zero calcium scores, p = 0.037; non-zero scores p = 0.061. 
C: Change in mean MDS TBR. Zero calcium scores, p < 0.001; non-zero scores p = 0.285. 
D: Change in MeanMaxTBR. Zero calcium scores, p = 0.010; non-zero scores p = 0.095. 
Least squares means and 95% CIs for absolute change from baseline. Two-sided p-values given for change at 6 
months from baseline for total (sum left and right) carotid calcium scores dichotomized into zero (blue) and non-
zero (red). 
CI = confidence interval; TBR = target-to-background ratio; MDS = most diseased segment; MeanMax, mean of 
maximum. 
